A-Z
ABCDEFGHIJKLMNOPQRSTUVWXYZ
α→σ
αβγδκμσ
Numbers
1457111214151719202326305053
New Products
View More
Drugs - Building Blocks
All Drugs List
Field
Target
Phase
Topics
Tumors more
Tumors are lesions of tissues or organs caused by the abnormal proliferation and differentiation of cells in the body. Tumors are classified into benign tumors and malignant tumors (cancer). Tumors are one of the hottest treatment areas today. Currently, there are 36,000+ oncology drugs under development worldwide. The treatment of tumors involves multiple directions, including targeted therapy, immunotherapy, chemotherapy, ADC therapy, gene therapy, cell therapy, etc.
Building Blocks Series
PROTAC Linkers more
In PROTAC molecules, PROTAC linkers are the connecting units that connect the target protein binding part and the E3 ubiquitin ligase. Linkers play a crucial role in PROTAC moleculars design because they can affect the biological activity, selectivity and pharmacokinetic properties of PROTACs.
Building Blocks CDMO
Selection and Design of BBs
MolScanner has the ability to independently screen building blocks, which come from a wide range of sources. The active small molecules downstream of these building blocks may come from the latest drug development patents, journals, or small molecules that are in the clinical research stage. These small molecule drugs cover all stages from drug discovery to clinical phase 3 and even market launch.
Learn More
R&D and Production of BBs
MolScanner leverages a specialized R&D and production team with decades of expertise in advanced organic synthesis. Core capabilities include building block synthesis, pharmaceutical intermediate development, and process optimization. Proficient in complex reactions such as catalytic hydrogenation, selective fluorination, alicyclicsystems and fused- ring synthesis, we deliver scalable solutions from lab to industrial production. Supported by advanced analytical systems and rigorous quality control, we tackle synthetic challenges through innovative methodologies, offering tailored synthesis strategies for intricate molecular architectures.
Learn More
Automated Synthetic Analysis Platform
MolScanner leverages the automated synthesis analysis platform created by Chemical.AI, including the AI retrosynthesis algorithm analysis platform - ChemAIRS, and the standard automated synthesis analysis laboratory - ChemAILab, to further enhance MolScanner's customized R&D capabilities.
Learn More
Process Development and Optimization
Looking at the entire new drug development process, pharmaceutical process development and optimization are the core stages of transitioning a drug from laboratory research to industrial-scale production. Building blocks (also known as pharmaceutical intermediates) are key materials in drug synthesis. The process development and optimization of building blocks directly determine the quality, cost, and production efficiency of the final Active Pharmaceutical Ingredient (API), which in turn affects the production quality, overall cost, and safety of the pharmaceutical product
Learn More
About Us
About MolScanner
MolScanner is a global brand of Chemical.AI that focuses on developing synthetic building blocks and pharmaceutical intermediates (collectively referred to as building blocks, BBs) that are cutting-edge, novel in structure, high in potential value, or critical to drug development. As Chemical.AI's core business segment in the field of building blocks, MolScanner leverages the strong advantages of parent company in the field of AI pharmaceuticals and combines its own CDMO business platform to provide building block design and synthesis route optimization services, efficient customized synthesis services, and production process development and optimization services for pharmaceutical R&D groups, scientific research institutions, and drug R&D laboratories around the world.
Learn More
Our Team
MolScanner has a professional chemical team and AI technical team, who have extensive experience in the design and mining of building blocks, synthesis of pharmaceutical intermediates, and the application of AI in drug synthesis. All team members have a bachelor's degree or above, and R&D personnel account for nearly 50%. At the same time, MolScanner has also formed a team with rich management experience, who maintain the normal development of projects, the normal operation of automated laboratories, and ensure the timely delivery of products with guaranteed quality and quantity.
Learn More
Facilities
MolScanner has a modern R&D laboratory of 3,000+ square meters, a pilot laboratory of 1,000+ square meters, a standardized production workshop equipped with multiple 1-3 ton reactors, an AI automated synthesis laboratory, and reaction devices required for various organic synthesis experiments. These cutting-edge reaction equipment can meet the quality requirements of industry standards and can be used to develop and produce different types of building blocks that meet drug synthesis standards.
Learn More
SUPPORT E-MAIL : support#molscanner.com